Domainex's newsletter brings you up to speed on the latest announcements from the team.
No images? Click here
Domainex newsletter
All the latest news and industry insights from the Domainex team
Tom Mander, CEO
New collaborations and progressing research
As the leaves start to turn and the nights draw in, it's great to be able to bring you some updates on the progress we're making, both inside and outside of the lab. We were thrilled to welcome back ex-CEO Dr Eddy Littler as Executive Chairman to help drive our continued growth. We also forged new relationships with Amphista Therapeutics and Lucy Cavendish College, further demonstrating the importance of collaboration throughout the scientific process.
The progression of DMXD-011 to be nominated as a preclinical drug candidate is a fantastic success for the whole team and our partners in the Netherlands. This offers a very attractive opportunity for a licensing partner to take these compounds into pre-clinical and clinical development - if you'd like to find out more, please get in touch.
Amphista Therapeutics partners with Domainex to advance portfolio of drug discovery projects targeting protein degradation
Amphista Therapeutics has selected Domainex as one of its trusted partners to provide integrated drug discovery services to support its research programmes. Domainex will provide expertise in protein production, assay biology and medicinal chemistry.
Anti-inflammatory drug candidate DMXD-011 shows efficacy in ex-vivo human studies
As a result of the work carried out by Domainex during an in-house research programme to identify inhibitors of the protein kinases TBK1 and IKK-epsilon, DMXD-011 has been nominated as a preclinical drug candidate. Recent human ex vivo data indicates this drug should be effective in the treatment of interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma.
Domainex appoints Eddy Littler as Executive Chairman
Dr Littler has a unique insight into Domainex, previously holding the roles of CEO (2008 - 2016) and Non-Executive Chairman (June - August 2020). He will have a pivotal role in leading the organisation through a continuing period of growth, expanding and strengthening the existing Executive Management Team.
Awards
Recognising our recent successes, we have been nominated for a number of awards:
- Winners - Global Health & Pharma International Life Sciences Awards
- Finalists - Cambridge Independent SME Cambridgeshire Business Awards 2022 - Business of the year more than 50 employees; High growth business of the year; Service Excellence - Winners announced today!
- Finalists - Scrip Awards 2022 - Business Development Team of the Year - Winners announced 30th November 2022
- Shortlist - Business Weekly Awards
Collaborating with Lucy Cavendish College
We recognise the challenges early career professionals face, especially when networks are limited. We are delighted to join the Lucy Cavendish Life Science Community and play our part in supporting the students through their time at the college, provide opportunities to build networks and gain experience and employment within the life science sector.
Meet the Domainex Team: Cameron Haddow
Cameron Haddow, Scientist, Assay Biology, tells us about starting his career with Domainex following his degree in biochemistry at the University of Bath and an industrial placement with AstraZeneca.
New recruits
Welcome to Thomas Peplow (Scientist, Assay Biology), Adam Wallington (Scientist, Chemistry), Yasmin Stone (Industrial Placement Student), Kamini Magon (Scientist, Assay biology), Anthony Jacovides (Scientist, Chemistry), Alicia Overall (Scientist, Assay Biology), Fergus Preston (Senior Scientist I, Chemistry), Panagiotis Fikas (Senior Scientist I, Chemistry), Darko Vukovic (Scientist, Chemistry) and Megan O’Brien (Industrial Placement Student) who have all joined the Domainex team. Visit our website to view the current available opportunities and find out more about working at Domainex.
Upcoming events
Discovery on Target
17th-18th October 2022 | Boston, United States
Highlighting advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
BIO-Europe 2022
24th-26th October 2022 | Leipzig, Germany
The preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors.
Genesis
7th December | London, UK
The annual Genesis conference has been a pillar of the Life Science sector for over two decades. Bringing together key opinion leaders, investors and innovators from across the sector to share insight, debate key trends and generate deals.
Postgraduate Symposium XVI – Biological and Medicinal Chemistry Symposium for Postgraduates 2022
9th December | Oxford, UK
Domainex is sponsoring and exhibiting at the Postgraduate Symposium XVI which will comprise of oral and poster presentations from PhD students and post-doctoral workers as well as keynote speakers from industry and academia.
